Interferon β treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology

被引:22
作者
Filippi, M
Rovaris, M
Capra, R
Gasperini, C
Prandini, F
Martinelli, V
Horsfield, MA
Bastianello, S
Sormani, MP
Pozzilli, C
Comi, G
机构
[1] Univ Milan, Osped San Raffaele, Inst Sci, Dept Neurosci,Neuroimaging Res Unit, I-20132 Milan, Italy
[2] Univ Milan, Osped San Raffaele, Inst Sci, Dept Neurosci,Clin Trials Unit, I-20132 Milan, Italy
[3] Univ Brescia, Spedali Civili, Dept Neurol, Brescia, Italy
[4] Univ Brescia, Spedali Civili, Dept Neuroradiol, Brescia, Italy
[5] Univ La Sapienza, Dept Neurol, Rome, Italy
[6] Univ La Sapienza, Dept Neuroradiol, Rome, Italy
[7] Univ Leicester, Div Med Phys, Leicester, Leics, England
[8] Natl Inst Canc Res, Unit Clin Epidemiol & Trials, Genoa, Italy
关键词
multiple sclerosis; interferon beta; magnetic resonance imaging;
D O I
10.1136/jnnp.67.3.386
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective-The ability of recombinant human interferon beta-1a (rh-IFN beta-1a) to suppress multiple sclerosis activity, evaluated from MRI, was assessed across a range of lesions enhancing at different gadolinium-DTPA (Gd) doses and with different sizes. Methods-Every 4 weeks, standard dose (Sd; 0.1 mmol/kg Gd) and triple dose (Td; 0.3 mmol/kgGd) MRI were obtained from 18 patients with relapsing-remitting multiple sclerosis for 3 months before and 4 months after starting treatment with 44 mu g rh-IFN beta-1a subcutaneously, once a week. Results-The total numbers of enhancing lesions were 145 and 126 on Sd scans and 278 and 192 on the Td scans obtained before and after treatment. The introduction of treatment decreased, on average, the rate of appearance of new enhancing lesions seen on Sd and Td scans by 37% (p<0.001). Treatment effects on new enhancing lesions seen on Td scans was, on average, 28% higher than on those seen on Sd scans. The distribution of lesion sizes on Td scans changed significantly during the treatment period (p=0.05), due to a marked decrease in the number of small lesions. Conclusions-The effect of 44 mu g rh-IFN beta-1a in reducing multiple sclerosis disease activity, as monitored by Gd enhanced MRI, is not homogeneous, but graduated according to the pathological characteristics and size of the lesions.
引用
收藏
页码:386 / 389
页数:4
相关论文
共 20 条
[1]   Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis [J].
Barkhof, F ;
Filippi, M ;
van Waesberghe, JH ;
Molyneux, P ;
Rovaris, M ;
Nijeholt, GLA ;
Tubridy, N ;
Miller, DH ;
Yousry, TA ;
Radue, EW ;
Adèr, HJ .
NEUROLOGY, 1997, 49 (06) :1682-1688
[2]   Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI [J].
Calabresi, PA ;
Stone, LA ;
Bash, CN ;
Frank, JA ;
McFarland, HF .
NEUROLOGY, 1997, 48 (05) :1446-1448
[3]  
DUQUETTE P, 1995, NEUROLOGY, V45, P1277
[4]   A high resolution three dimensional T-1-weighted gradient echo sequence improves the detection of disease activity in multiple sclerosis [J].
Filippi, M ;
Yousry, T ;
Horsfield, MA ;
Alkadhi, H ;
Rovaris, M ;
Campi, A ;
Voltz, R ;
Comi, G .
ANNALS OF NEUROLOGY, 1996, 40 (06) :901-907
[5]   Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS [J].
Filippi, M ;
Yousry, T ;
Campi, A ;
Kandziora, C ;
Colombo, B ;
Voltz, R ;
Martinelli, V ;
Spuler, S ;
Bressi, S ;
Scotti, G ;
Comi, G .
NEUROLOGY, 1996, 46 (02) :379-384
[6]   Magnetization transfer ratios in multiple sclerosis lesions enhancing after different doses of gadolinium [J].
Filippi, M ;
Rocca, MA ;
Rizzo, G ;
Horsfield, MA ;
Rovaris, M ;
Minicucci, L ;
Colombo, B ;
Comi, G .
NEUROLOGY, 1998, 50 (05) :1289-1293
[7]   A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis -: Implications for phase II clinical trials [J].
Filippi, M ;
Rovaris, M ;
Capra, R ;
Gasperini, C ;
Yousry, TA ;
Sormani, MP ;
Prandini, F ;
Horsfield, MA ;
Martinelli, V ;
Bastianello, S ;
Kühne, I ;
Pozzilli, C ;
Comi, G .
BRAIN, 1998, 121 :2011-2020
[8]   Intramuscular interferon beta-1 alpha for disease progression in relapsing multiple sclerosis [J].
Jacobs, LD ;
Cookfair, DL ;
Rudick, RA ;
Herndon, RM ;
Richert, JR ;
Salazar, AM ;
Fischer, JS ;
Goodkin, DE ;
Granger, CV ;
Simon, JH ;
Alam, JJ ;
Bartoszak, DM ;
Bourdette, DN ;
Braiman, J ;
Brownscheidle, CM ;
Coats, ME ;
Cohan, SL ;
Dougherty, DS ;
Kinkel, RP ;
Mass, MK ;
Munschauer, FE ;
Priore, RL ;
Pullicino, PM ;
Scherokman, BJ ;
WeinstockGuttman, B ;
Whitman, RH ;
Baird, WC ;
Fillmore, M ;
Bona, LM ;
ColonRuiz, ME ;
Nadine, BS ;
Donovan, A ;
Bennett, S ;
Kieffer, YM ;
Umhauer, MA ;
Miller, CE ;
Kilic, AK ;
Sargent, EL ;
Schachter, M ;
Shucard, DW ;
Weider, V ;
Catalano, BA ;
Cervi, JM ;
Czekay, C ;
Farrell, JL ;
Filippini, JS ;
Matyas, RC ;
Michienzi, KE ;
Ito, M ;
OMalley, JA .
ANNALS OF NEUROLOGY, 1996, 39 (03) :285-294
[9]  
KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444
[10]   Defining the clinical course of multiple sclerosis: Results of an international survey [J].
Lublin, FD ;
Reingold, SC .
NEUROLOGY, 1996, 46 (04) :907-911